endosergЭндокринная хирургияEndocrine Surgery2306-35132310-3965Типография «Печатных дел Мастер»10.14341/2306-3513-2012-1-37-44endoserg-4013Research ArticleСтатьиArticlesНовости мировой эндокринной хирургииWorld endocrine surgery newsKarseladzeE A-20121503201261№1 (2012)3744Copyright © Karseladze E.A., 20122012Karseladze E.A.Karseladze E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surg-endojournals.ru/jour/article/view/4013ReferencesAl-Adhami A., Craig W., Krukowski Z. Quality of life after surgery for Graves' disease. Thyroid 2012; Jan 12Al-Adhami A., Craig W., Krukowski Z. Quality of life after surgery for Graves' disease. Thyroid 2012; Jan 12Shah M.D., Harris L.D., Nassif R.G. et al. Efficacy and safety of central compartment neck dissection for recurrent thyroid carcinoma. Arch. Otolaryngol. Head. Neck. Surg. 2012;138 (1): 33–37Shah M.D., Harris L.D., Nassif R.G. et al. Efficacy and safety of central compartment neck dissection for recurrent thyroid carcinoma. Arch. Otolaryngol. Head. Neck. Surg. 2012;138 (1): 33–37Paulson L., Shindo M., Schuff K. et al. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch. Otolaryngol. Head. Neck. Surg. 2012; 138 (1): 44–49Paulson L., Shindo M., Schuff K. et al. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch. Otolaryngol. Head. Neck. Surg. 2012; 138 (1): 44–49Wells S.A. Jr., Robinson B.G., Gagel R.F. et al. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. J. Clin. Oncol. 2012; 10;30 (2):134–141Wells S.A. Jr., Robinson B.G., Gagel R.F. et al. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. J. Clin. Oncol. 2012; 10;30 (2):134–141Eisenhofer G., Lenders J.W., Siegert G. et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur. J. Cancer. 2011; Oct 28Eisenhofer G., Lenders J.W., Siegert G. et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur. J. Cancer. 2011; Oct 28Winer K.K., Zhang B., Shrader J.A. et al. Synthetic Human Parathyroid Hormone 1-34 Replacement Therapy: A Randomized Crossover Trial Comparing Pump Versus Injections in the Treatment of Chronic Hypoparathyroidism. J. Clin. Endocrinol. Metab. 2011; Nov 16Winer K.K., Zhang B., Shrader J.A. et al. Synthetic Human Parathyroid Hormone 1-34 Replacement Therapy: A Randomized Crossover Trial Comparing Pump Versus Injections in the Treatment of Chronic Hypoparathyroidism. J. Clin. Endocrinol. Metab. 2011; Nov 16Fusco A., Giampietro A., Bianchi A. Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary. 2011; Dec 30Fusco A., Giampietro A., Bianchi A. Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary. 2011; Dec 30Oberstein P.E., Saif M.W. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin. Med. Insights. Oncol. 2012; 6: 41–51Oberstein P.E., Saif M.W. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin. Med. Insights. Oncol. 2012; 6: 41–51Kubota T., Ohyama S., Hiki N. et al. Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute. Gastric. Cancer. 2012; Jan 18Kubota T., Ohyama S., Hiki N. et al. Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute. Gastric. Cancer. 2012; Jan 18Chellan G., Neethu K., Varma A.K. et al. Targeted treatment of invasive fungal infections accelerates healing of foot wounds in patients with Type 2 diabetes. Diabet. Med. 2012; Jan 16Chellan G., Neethu K., Varma A.K. et al. Targeted treatment of invasive fungal infections accelerates healing of foot wounds in patients with Type 2 diabetes. Diabet. Med. 2012; Jan 16
The authors declare that there are no conflicts of interest present.